Compass Pathways, which is creating a psilocybin remedy for extreme despair, stated Tuesday it now expects a possible approval resolution from U.S. regulators in late 2026 or early 2027, 9 to 12 months sooner than beforehand anticipated.
Following what it described as a “constructive” assembly with the Meals and Drug Administration, Compass is now planning for a rolling submission, during which it submits outcomes of trials as they full and the company critiques the info because it receives them. If authorised, Compass’ drug could be the primary psilocybin remedy in the marketplace.
The FDA doesn’t touch upon conferences with drugmakers forward of its choices, however the expedited timeline seems to sign the company’s curiosity in psychedelics. Well being Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary have each voiced assist for the event of the medicine, main proponents to hope the company will assist get them in the marketplace sooner.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.